• Explore /
  • Poster
  • / Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice.

Prospective, multi-center study of 5-fluorouracil (5-FU) therapeutic drug management (TDM) in metastatic colorectal cancer (mCRC) patients treated in routine clinical practice.

Abstract Poster

Authors

Salvatore J. Salamone

Salvatore J. Salamone

Saladax Biomedical, Inc., Bethlehem, PA

Salvatore J. Salamone , Ulrich Jaehde , Lothar Mueller , Karin Link , Stefan Holdenrieder , Thomas Bertsch , Yon-Dschun Ko , Volker Kunzmann , Ingo Suttmann , Jan Braess , Max Roessler , Berta Moritz , Stefanie Kraff , Michael Craig Miller , Martin Wilhelm

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

2011-003553-26

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 650)

DOI

10.1200/JCO.2017.35.4_suppl.650

Abstract #

650

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Celalettin Camci

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.

A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.

First Author: Akshit Chitkara

First Author: Yu Sunakawa

First Author: Candice Baldeo